<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04691427</url>
  </required_header>
  <id_info>
    <org_study_id>OMT-01</org_study_id>
    <nct_id>NCT04691427</nct_id>
  </id_info>
  <brief_title>Effectiveness of Virtual Reality Vision Therapy - VERVE</brief_title>
  <acronym>VRVT - VERVE</acronym>
  <official_title>Effectiveness of Vision Therapy in a Virtual Reality Headset</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>OculoMotor Technologies</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>New Jersey Institute of Technology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Salus University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>OculoMotor Technologies</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to see how well the treatment of a participant's eye&#xD;
      coordination and/or focusing problems improves eye muscle responses and symptoms of&#xD;
      eyestrain. We will use an entertainment device called a virtual reality headset to play a&#xD;
      custom-designed video game to find out how well the treatment of binocular vision improves a&#xD;
      participant's coordination and/or focusing problem. The virtual reality headset uses&#xD;
      eye-trackers to monitor progress in a totally objective manner. Objective testing allows the&#xD;
      doctor to determine the results without relying on a participant's ability to answer&#xD;
      questions or respond verbally in any way. We will compare the results of a participant before&#xD;
      and after playing the video game.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 14, 2021</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Examiner (Outcomes Assessor) will be masked by pooling participants from another study.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Positive Fusional Vergence</measure>
    <time_frame>up to 4 weeks post-therapy</time_frame>
    <description>Normal range is &gt;15 Prism Diopters</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Near Point of Convergence</measure>
    <time_frame>up to 4 weeks post-therapy</time_frame>
    <description>Normal range is &lt; 6 cm</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Convergence Insufficiency Symptom Survey (CISS)</measure>
    <time_frame>up to 4 weeks post-therapy</time_frame>
    <description>Normal range is &lt; 21 for adults and &lt; 16 for pediatrics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vision Quality of Life with Time Survey (VisQuaL-T)</measure>
    <time_frame>up to 4 weeks post-therapy</time_frame>
    <description>Normal range is &gt; 2.5</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Core Elements of Gaming Experience Questionnaire</measure>
    <time_frame>up to 4 weeks post-therapy</time_frame>
    <description>User experience rating</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Convergence Insufficiency</condition>
  <arm_group>
    <arm_group_label>Active Virtual Reality-Based Vision Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Virtual reality vision therapy where participants will be playing a custom-designed video game to act as a therapeutic intervention on a consumer-available virtual reality headset.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Virtual Eye Rotation Vision Exercises (VERVE)</intervention_name>
    <description>A video game designed with elements of vision therapy will be delivered to participants utilizing consumer-available virtual reality headsets (VIVE Pro Eye).</description>
    <arm_group_label>Active Virtual Reality-Based Vision Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 9 years and older&#xD;
&#xD;
          -  CISS score ≥ 16&#xD;
&#xD;
          -  Best-corrected distance visual acuity of 20/25 or better in each eye&#xD;
&#xD;
          -  Random dot stereopsis appreciation of 500 seconds of arc or better&#xD;
&#xD;
          -  Parent or subject understands the protocol and is willing to enroll in the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Constant strabismus at distance or near&#xD;
&#xD;
          -  Vertical heterophoria ≥ 2 ∆ at distance or near&#xD;
&#xD;
          -  ≥ 2 line interocular difference in best-corrected visual acuity&#xD;
&#xD;
          -  Near point of accommodation &gt; 20 cm in either eye as measured by push-up method&#xD;
&#xD;
          -  Manifest or latent nystagmus&#xD;
&#xD;
          -  Non-strabismic binocular vision and accommodative disorders associated with head&#xD;
             trauma or known disease of the brain&#xD;
&#xD;
          -  Diseases known to affect accommodation, vergence, or ocular motility such as multiple&#xD;
             sclerosis, Graves orbitopathy, myasthenia gravis, diabetes mellitus, Parkinson disease&#xD;
&#xD;
          -  Any ocular or systemic medication known to affect accommodation or vergence such as&#xD;
             anti-anxiety agents (e.g., Librium or Valium), anti-arrhythmic agents (e.g.,&#xD;
             Cifenline, Cibenzoline), anti-cholinergics, bladder spasmolytic drugs (e.g.,&#xD;
             Propiverine), hydroxychloroquine, chloroquine, phenothiazines (e.g., Compazine,&#xD;
             Mellaril, Thorazine), tricyclic antidepressants (e.g., Elavil, Nortriptyline,&#xD;
             Tofranil)&#xD;
&#xD;
          -  Inability to comprehend and/or perform any study-related test or procedure&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chang Yaramothu, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>OculoMotor Technologies</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tara L Alvarez, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>OculoMotor Technologies</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mitchell M Scheiman, OD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>OculoMotor Technologies</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chang Yaramothu, PhD</last_name>
    <phone>9735585456</phone>
    <email>cto@omtvr.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>OculoMotor Technologies</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chang Yaramothu, PhD</last_name>
      <email>cto@omtvr.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Eye Institute at Salus University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19141</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mitchell Scheiman, OD, PhD</last_name>
      <email>cmo@omtvr.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>December 15, 2020</study_first_submitted>
  <study_first_submitted_qc>December 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 31, 2020</study_first_posted>
  <last_update_submitted>October 20, 2021</last_update_submitted>
  <last_update_submitted_qc>October 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ocular Motility Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

